Display options
Cite
Swartz MM, Linn DM, Linn CL. Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action. Neuropharmacology. 2013;73:111-21doi: 10.1016/j.neuropharm.2013.05.020.
Swartz, M. M., Linn, D. M., & Linn, C. L. (2013). Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action. Neuropharmacology, 73111-21. https://doi.org/10.1016/j.neuropharm.2013.05.020
Swartz, Michael M, et al. "Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action." Neuropharmacology vol. 73 (2013): 111-21. doi: https://doi.org/10.1016/j.neuropharm.2013.05.020
Swartz MM, Linn DM, Linn CL. Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action. Neuropharmacology. 2013 Oct;73:111-21. doi: 10.1016/j.neuropharm.2013.05.020. Epub 2013 May 29. PMID: 23727438; PMCID: PMC3766469.
Copy Download .nbib Format: NLM
Share it on

Neuropharmacology. 2013 Oct;73:111-21. doi: 10.1016/j.neuropharm.2013.05.020. Epub 2013 May 29.

Tropisetron as a neuroprotective agent against glutamate-induced excitotoxicity and mechanisms of action.

Neuropharmacology

Michael M Swartz, David M Linn, Cindy L Linn

Affiliations

  1. Western Michigan University, Department of Biological Sciences, Kalamazoo, MI 49008, USA.

PMID: 23727438 PMCID: PMC3766469 DOI: 10.1016/j.neuropharm.2013.05.020

Abstract

The objective of this study was to determine the neuroprotective role of tropisetron on retinal ganglion cells (RGCs) as well as to explore the possible mechanisms associated with alpha7 nAChR-induced neuroprotection. Adult pig RGCs were isolated from all other retinal tissue using a two-step panning technique. Once isolated, RGCs were cultured for 3 days under control untreated conditions, in the presence of 500 μM glutamate to induce excitotoxicity, and when tropisetron was applied before glutamate to induce neuroprotection. 500 μM glutamate decreased RGC survival by an average of 62% compared to control conditions. However, RGCs pretreated with 100 nM tropisetron before glutamate increased cell survival to an average of 105% compared to controls. Inhibition studies using the alpha7 nAChR antagonist, MLA (10 nM), support the hypothesis that tropisetron is an effective neuroprotective agent against glutamate-induced excitotoxicity; mediated by α7 nAChR activation. ELISA studies were performed to determine if signaling cascades normally associated with excitotoxicity and neuroprotection were up- or down-regulated after tropisetron treatment. Tropisetron had no discernible effects on pAkt levels but significantly decreased p38 MAPK levels associated with excitotoxicity from an average of 15 ng/ml to 6 ng/ml. Another mechanism shown to be associated with neuroprotection involves internalization of NMDA receptors. Double-labeled immunocytochemistry and electrophysiology studies provided further evidence that tropisetron caused internalization of NMDA receptor subunits. The findings of this study suggest that tropisetron could be an effective therapeutic agent for the treatment of degenerative disorders of the central nervous system that involves excitotoxicity.

Copyright © 2013 Elsevier Ltd. All rights reserved.

Keywords: (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1methyl-indole-3-carboxylate; 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride; 5-HT(3); ACh; AEBSF; ANOVA; CNS; EDTA; EGTA; ELISA; Excitotoxicity; FBS; GluRs; IgG; IgM; MAPK; MLA; N-methyl-d-aspartate; NGF; NMDA; Neuroprotection; PBS; PMSF; Pig; RGC; Retina; Retinal ganglion cells; SDS; TEA; Thy; Tropisetron; acetylcholine; alpha7 nicotinic acetylcholine receptor; analysis-of-variance; central nervous system; enzyme-linked immunosorbent assay; ethylene glycol tetraacetic acid; ethylenediaminetetraacetic acid; fetal bovine serum; glutamate receptors; glycoprotein originally identified in thymus gland; immunoglobulin G; immunoglobulin M; methyllycaconitine; mitogen activated protein kinase; nAChR; nerve growth factor; nicotinic acetylcholine receptor; phenylmethylsulfonyl fluoride; phosphate buffered saline; retinal ganglion cell; serotonin; sodium dodecyl sulfate; tetraethylammonium chloride; tropisetron; α7 nAChR

References

  1. Neuroscience. 2011 Jan 13;172:387-97 - PubMed
  2. J Alzheimers Dis. 2011;24 Suppl 2:95-109 - PubMed
  3. J Neurochem. 2011 Sep;118(6):1113-23 - PubMed
  4. J Biol Chem. 2001 Apr 27;276(17):13541-6 - PubMed
  5. J Neurophysiol. 1994 Sep;72(3):1260-9 - PubMed
  6. Mol Vis. 2007 Aug 28;13:1496-507 - PubMed
  7. Cell Res. 2005 Jan;15(1):11-8 - PubMed
  8. J Neurochem. 2010 Jan;112(1):214-26 - PubMed
  9. Cell Calcium. 2003 Oct-Nov;34(4-5):325-37 - PubMed
  10. Invest Ophthalmol Vis Sci. 2004 May;45(5):1531-43 - PubMed
  11. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):385-92 - PubMed
  12. Prog Neurobiol. 1997 Oct;53(2):199-237 - PubMed
  13. Exp Eye Res. 2006 Nov;83(5):1135-45 - PubMed
  14. J Neurochem. 1998 Sep;71(3):946-59 - PubMed
  15. J Mol Med (Berl). 2000;78(1):3-13 - PubMed
  16. Neuroscience. 2007 Nov 23;149(4):908-16 - PubMed
  17. J Neuroinflammation. 2012 May 24;9:98 - PubMed
  18. Curr Neuropharmacol. 2008 Jun;6(2):164-78 - PubMed
  19. J Neurosci. 2012 May 16;32(20):6967-80 - PubMed
  20. Trends Neurosci. 2005 Jul;28(7):371-8 - PubMed
  21. Cell Biol Int. 2007 Sep;31(9):1027-35 - PubMed
  22. J Physiol. 1990 Sep;428:175-97 - PubMed
  23. Neuroscience. 2006;138(1):17-24 - PubMed
  24. Front Mol Neurosci. 2012 Apr 13;5:39 - PubMed
  25. Endocr Rev. 2001 Apr;22(2):153-83 - PubMed
  26. J Neurosci. 1988 Aug;8(8):2895-906 - PubMed
  27. Neuropharmacology. 2000 Oct;39(13):2799-807 - PubMed
  28. Cell. 1997 Nov 14;91(4):479-89 - PubMed
  29. Prog Retin Eye Res. 1998 Oct;17(4):465-83 - PubMed
  30. J Neurosci. 2010 Apr 28;30(17):5948-57 - PubMed
  31. J Neurosci. 2013 Feb 27;33(9):4151-64 - PubMed
  32. Br J Pharmacol. 2010 Sep;161(1):127-39 - PubMed
  33. J Neurosci. 2001 Jun 15;21(12):4125-33 - PubMed
  34. Prog Neurobiol. 1998 Mar;54(4):369-415 - PubMed
  35. Brain Res. 1994 May 2;644(2):181-7 - PubMed
  36. J Neurochem. 2000 Jan;74(1):134-42 - PubMed
  37. Vision Res. 1997 Dec;37(24):3483-93 - PubMed
  38. Nature. 1984 May 17-23;309(5965):261-3 - PubMed
  39. Neuropharmacology. 2009 Jan;56(1):2-5 - PubMed
  40. Neuroscience. 2004;125(3):583-90 - PubMed
  41. Bioorg Med Chem Lett. 2001 Feb 12;11(3):319-21 - PubMed
  42. J Physiol. 2006 Sep 1;575(Pt 2):543-54 - PubMed
  43. J Neurochem. 2011 Nov;119(4):848-58 - PubMed
  44. Pflugers Arch. 1981 Aug;391(2):85-100 - PubMed
  45. Brain Res. 1997 Aug 8;765(1):135-40 - PubMed
  46. Am J Physiol Cell Physiol. 2003 Mar;284(3):C757-68 - PubMed
  47. Neurosci Lett. 2005 Apr 22;378(3):140-4 - PubMed
  48. J Neurosci. 1993 Jul;13(7):2874-88 - PubMed
  49. Synapse. 1999 Jun 15;32(4):262-75 - PubMed
  50. J Physiol. 1995 Jan 15;482 ( Pt 2):309-15 - PubMed
  51. Curr Opin Pharmacol. 2007 Feb;7(1):39-47 - PubMed
  52. Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1096-106 - PubMed

Substances

MeSH terms

Publication Types

Grant support